3Hadziyannis S,Tassopoulos N,Chang TT,et al.Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long-term safety and efficacy study.J Hepatol,2004,40(Suppl 1):17 (Abstract 46).
4Hadziyannis SJ,Papatheodoridis GV.Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.Expert Rev Anti Infect Ther,2004,2:475-483.
5Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med,2003,348:808-816.
6Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N Engl J Med,2003,348:800-807.
7Cullen JM,Li DH,Brown C,et al.Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.Antimicrob Agents Chemother,2001,45:2740-2745.
8Delmas J,Schorr O,Jamard C,et al.Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.Antimicrob Agents Chemother,2002,46:425-433.
9Werle-Lapostolle B,Bowden S,Locarnini S,et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.Gastroenterology,2004,126:1750-1758.
10Lok AS,McMahon BJ.Chronic hepatitis B:update of recommendations.Heptology,2004,39:857-861.
1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
